Editor's Choice:  Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer

Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection

Hosted by: 

Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada

Featuring: 

Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA

Alexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA

Jose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial

Editorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE trial

Hosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada

Featuring: Janice S. Kwon  MD, MPH, FRCSC, University of British Columbia, Vancouver, Canada and  R. Wendel Naumann, MD Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28203, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?

Editorial: Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer

Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology

Featuring:
Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA
Christina M. Annunziata, American Cancer Society, Atlanta, GA, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches

Editorial: Who is following up? Rethinking survivorship and surveillance

Hosted by: Paola A Gehrig, MD University of Virginia Charlottesville, Virginia United States

Featuring:
Lee-may Chen, MD; Division of Gynecologic Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States
Esther Vermaas; Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
J.W.M. Aarts, MD, PhD; Principal Investigator and Gynaecological oncologist Amsterdam University Medical Centers, location VUMC, the Netherland

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant

Editorial: Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 carriers:Why is this a question?

Hosted by:
John Farley, MD, COL(ret), FACOG, FACS, St Joseph's Hospital and Medical Center, Phoenix, AZ, United States of America

Featuring:
Steven Narod, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada
Stephanie Blank, Icahn School of Medicine at Mount Sinai,  New York, NY, USA
Melissa K. Frey, Weill Cornell Medicine, New York, NY, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

Editor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer

Editorial: From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology

Hosted by:
Paola Gehrig, MD, Associate Editor of Gynecologic Oncology

Featuring:
Bradley Corr, University of Colorado, Aurora, CO, USA
Ursula Matulonis, Dana-Farber Cancer Institute, Boston, MA, USA
Mary M. Mullen, Washington University School of Medicine, St Louis, MO, USA
Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer

Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
Chiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
Oliver Zivanovic, Clinic for Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S

Editorial: Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment

Editorial: Minimum standards for radiation therapy in the treatment of cervical cancer in the U.S.: A consensus statement by SGO, ASTRO, and ABS addressing the WHO Cervical Cancer Elimination Campaign goals

Hosted by:
Dr. Warner Huh, Associate Editor of Gynecologic Oncology

Featuring:
Drs. Charles A. Leath, University of Alabama at Birmingham, Birmingham, AL, USA

 Junzo Chino, Duke University Medical Center, Durham, NC, USA

 Shane Neibart, Brigham and Women's Hospital, Boston, MA, USA

Nancy Zhou, Rutgers New Jersey Medical School, Newark, NJ, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trial

Editorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptoms

Hosted by:
Jose Alejandro Rauh-Hain, MD, Associate Editor of Gynecologic Oncology
Featuring:
Larissa Alejandra Meyer, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Stacy D. D'Andre, Department of Oncology, Mayo Clinic, Rochester, MN, United States

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net